United Therapeutics insider discloses September sales totaling 52,000 shares

Rhea-AI Filing Summary

UNITED THERAPEUTICS (UTHR) Form 144 filing: An insider, Martine Rothblatt, notified the sale of 4,000 common shares through TD Securities with an approximate aggregate market value of $1,723,659, and the filing lists the issuer's outstanding common shares as 45,230,000. The securities reported were originally acquired on 03/15/2016 as part of an executive deferred compensation arrangement totaling 294,000 shares, with payment made via exercised vested options. The filing also discloses multiple prior open-market sales by the same person during September 2025, totaling 52,000 shares across listed dates and generating the gross proceeds shown per trade. The filer certifies no undisclosed material adverse information.

Positive

• Full Rule 144 disclosure provided with acquisition details and broker information
• Recent open-market sales are transparently itemized with dates and gross proceeds
• Filer certifies no undisclosed material adverse information, reducing regulatory ambiguity

Negative

• Insider selling activity totaling 52,000 shares in September 2025 may attract investor scrutiny despite being small relative to outstanding shares

Insights

Financial Analyst

TL;DR: Insider has sold a sequence of shares; disclosed sales are small relative to outstanding stock and likely neutral to valuation.

The filing shows planned sale of 4,000 shares and a record of recent sales aggregating 52,000 shares by the insider. Relative to the company's 45.23 million outstanding shares, these transactions represent a small percentage of float (well under 1%). From a capital-markets perspective, routine Rule 144 sales and use of a broker are standard liquidity actions following vested option exercises. No financial results, covenant changes, or new agreements are disclosed, limiting material impact on fundamentals.

Corporate Governance Expert

TL;DR: The disclosure satisfies Rule 144 reporting requirements and signals compliance, though repeated insider sales may draw investor attention.

The notice provides required details: acquisition date, nature of acquisition (executive deferred compensation), broker information, and a history of recent open-market sales with gross proceeds. The signer affirms lack of undisclosed material adverse information and references Rule 10b5-1 mechanics where applicable. Governance-wise, transparent reporting reduces regulatory risk; however, the pattern of multiple sales in a short period could prompt governance-focused stakeholders to seek context even if sales are procedurally compliant.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
COMMON	TD SECURITIES (USA) LLC 125 PARK AVE, 20Th Floor New York NY 10017	4000	1723659.00	45230000	09/25/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
COMMON	03/15/2016	Executive Deferred Compensation	Martine Rothblatt			294000	03/15/2016	Shares exercised via vested options and payment made via common shares

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Martine Rothblatt 1000 Spring Street Silver Spring MD 20910	Common	09/09/2025	8000	3188374.33
Martine Rothblatt 1000 Spring Street Silver Spring MD 20910	Common	09/10/2025	4000	1594872.82
Martine Rothblatt 1000 Spring Street Silver Spring MD 20910	Common	09/11/2025	4000	1588904.00
Martine Rothblatt 1000 Spring Street Silver Spring MD 20910	Common	09/12/2025	4000	1615897.79
Martine Rothblatt 1000 Spring Street Silver Spring MD 20910	Common	09/15/2025	4000	1591535.70
Martine Rothblatt 1000 Spring Street Silver Spring MD 20910	Common	09/16/2025	4000	1601062.04
Martine Rothblatt 1000 Spring Street Silver Spring MD 20910	Common	09/17/2025	4000	1600686.85
Martine Rothblatt 1000 Spring Street Silver Spring MD 20910	Common	09/18/2025	4000	1617665.13
Martine Rothblatt 1000 Spring Street Silver Spring MD 20910	Common	09/19/2025	4000	1644310.00
Martine Rothblatt 1000 Spring Street Silver Spring MD 20910	Common	09/22/2025	4000	1669212.50
Martine Rothblatt 1000 Spring Street Silver Spring MD 20910	Common	09/23/2025	4000	1672512.50
Martine Rothblatt 1000 Spring Street Silver Spring MD 20910	Common	09/24/2025	4000	1736408.50

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What share sale is being reported in the UTHR Form 144?

The filing reports a proposed sale of 4,000 common shares through TD Securities with an aggregate market value of $1,723,659.

Who is the seller named in the Form 144 for UTHR?

The seller is Martine Rothblatt, identified as the person for whose account the securities are to be sold.

When were the securities being sold originally acquired?

The securities were acquired on 03/15/2016 under an executive deferred compensation arrangement; payment was via exercised vested options.

How many shares did the insider sell during the listed September 2025 dates?

The filing lists open-market sales on multiple dates in September 2025 totaling 52,000 shares across the reported transactions.

What percentage of UTHR's outstanding shares do these sales represent?

The filing states 45,230,000 shares outstanding; the listed 52,000-share sales are a small fraction of that total (well under 1%).

Does the Form 144 indicate any undisclosed material adverse information?

No; the filer signs a representation that they do not know of any material adverse information about the issuer that has not been publicly disclosed.